Literature DB >> 33609610

CircRNA in cancer: Fundamental mechanism and clinical potential.

Liang Chen1, Ge Shan2.   

Abstract

Circular RNAs (CircRNAs) are a class of single-stranded noncoding RNAs that are formed in a circular conformation via non-canonical splicing or back-splicing events. Aberrant expressions of many circRNAs are observed in diverse cancers, indicating their crucial roles in tumorigenesis and tumor development. Recently, several pieces of evidence have revealed that many circRNAs are involved in the promotion or suppression of cancers to varying degrees via different molecular mechanisms. Here in this review, we present a summary of the characteristics, types, biogenesis, and functions of circRNAs, and outline a series of the most recently studied circRNAs and their functional mechanisms in multiple cancer types with future perspectives. With great advances in nucleic acid-based therapeutic tools, circRNAs could be further explored as targetable molecules in future cancer treatments.0.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Back-splicing; Circular RNA; Dysregulation; RNA binding proteins; miRNA sponge

Year:  2021        PMID: 33609610     DOI: 10.1016/j.canlet.2021.02.004

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  29 in total

1.  Expression of CircATXN7 in esophageal cancer tissues and its effect on cell proliferation and invasion.

Authors:  Delin Liu; Hui Jia; Jianwei Lu; Xi Zou; Ting Qian; Fanyu Peng; Guochun Cao; Min Wang; Shenlin Liu
Journal:  J Gastrointest Oncol       Date:  2022-06

2.  Targeting the androgen receptor to enhance NK cell killing efficacy in bladder cancer by modulating ADAR2/circ_0001005/PD-L1 signaling.

Authors:  Qing Liu; Bosen You; Jialin Meng; Chi-Ping Huang; Guanglu Dong; Ronghao Wang; Fuju Chou; Shan Gao; Chawnshang Chang; Shuyuan Yeh; Wanhai Xu
Journal:  Cancer Gene Ther       Date:  2022-08-01       Impact factor: 5.854

3.  Circ_0002476 regulates cell growth, invasion, and mtDNA damage in non-small cell lung cancer by targeting miR-1182/TFAM axis.

Authors:  Weijie Wang; Haiting Sun; Xuan Ma; Ting Zhu; Haina Zhang
Journal:  Thorac Cancer       Date:  2022-09-03       Impact factor: 3.223

Review 4.  Emerging roles of circular RNAs in gastric cancer metastasis and drug resistance.

Authors:  Xiaolin Wang; Jiahui Zhang; Guozhen Cao; Jinghan Hua; Ge Shan; Wenchu Lin
Journal:  J Exp Clin Cancer Res       Date:  2022-07-11

Review 5.  Circular RNAs in hepatocellular carcinoma: Recent advances.

Authors:  Zhao-Shan Niu; Wen-Hong Wang
Journal:  World J Gastrointest Oncol       Date:  2022-06-15

Review 6.  Mutual regulation between N6-methyladenosine (m6A) modification and circular RNAs in cancer: impacts on therapeutic resistance.

Authors:  Hong Lin; Yuxi Wang; Pinghan Wang; Fangyi Long; Ting Wang
Journal:  Mol Cancer       Date:  2022-07-18       Impact factor: 41.444

7.  circEXOC6B interacting with RRAGB, an mTORC1 activator, inhibits the progression of colorectal cancer by antagonizing the HIF1A-RRAGB-mTORC1 positive feedback loop.

Authors:  Xiaomin Li; Jianjun Wang; Weihao Lin; Qinzi Yuan; Yanxia Lu; Haowei Wang; Yujia Chen; Lixia Chen; Peiling Dai; Huaicheng Long; Xuenong Li
Journal:  Mol Cancer       Date:  2022-06-23       Impact factor: 41.444

8.  Circ_0001658 regulates PI3K/AKT signaling via the miR-671-5p/ITGA2 axis and affects the progress of papillary thyroid carcinoma.

Authors:  Xiaoyu Liu; Congren Wang; Zijian Su; Shaoyang Cai; Qunxiong Pan; Xiangjin Chen
Journal:  Ann Transl Med       Date:  2022-09

9.  CircRNAs as potent biomarkers in ovarian cancer: a systematic scoping review.

Authors:  Zahra Foruzandeh; Fatemeh Zeinali-Sehrig; Kazem Nejati; Dara Rahmanpour; Fariba Pashazadeh; Farhad Seif; Mohammad Reza Alivand
Journal:  Cell Mol Biol Lett       Date:  2021-09-23       Impact factor: 5.787

10.  CircMET promotes tumor proliferation by enhancing CDKN2A mRNA decay and upregulating SMAD3.

Authors:  Lei Yang; Yi Chen; Ning Liu; Yanwen Lu; Wenliang Ma; Zhenhao Yang; Weidong Gan; Dongmei Li
Journal:  Mol Cancer       Date:  2022-01-18       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.